QGQingtian Gong

Qingtian Gong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qingtian Gong has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structural basis for autoinhibition and self-activation in the Pseudomonas aeruginosa virulence factor protease IV (PIV)

    by Christopher J. Harding, Carlin Hamill, Qingtian Gong, Clarissa Melo Czekster

    Secreted proteases enable Pseudomonas aeruginosa to damage host tissues and evade host immune defences, but the molecular basis by which protease IV (PIV) is maintained as an inactive precursor remains unclear. Here we determined a 2.17 A crystal structure of catalytically inactive PIVS409A. The precursor comprises an N-terminal Cap region, a CUB domain and a C-terminal trypsin-like protease domain. The Cap region forms an extended clamp across the precursor, and residues at the Cap-CUB junction lie above the catalytic cleft. Structural comparison with a modelled peptide substrate indicates that the Cap does not engage the substrate-recognition pockets as a pseudosubstrate; instead, it sterically prevents access to the S1 pocket, oxyanion hole and catalytic triad. Wild-type PIV undergoes progressive processing to a 27.6-kDa mature species, whereas the S409A variant remains resistant to activation by exogenous mature enzyme, supporting an intramolecular initiating step. Mature PIV is weakly inhibited by an ornithine-containing peptide mimicking the Cap domain, is not inhibited by phenylmethylsulfonyl fluoride and is slowly irreversibly inhibited by TLCK, demonstrating unique characteristics in comparison to other proteases from the same family. Finally, mature PIV increases the activity of aminopeptidase PaAP, likely through maturation of this enzyme, as part of a protease activation cascade. These findings define the architecture of the PIV precursor and provide a structural framework for understanding its activation and selective autoinhibition.

  • Open Access

    Bacterial Aminopeptidase-Activated Peptide Prodrug Enables Species-Selective Targeting of Pseudomonas aeruginosa

    by Qingtian Gong, Silvia Synowsky, Aisling Lynch, John R. F. B. Connolly, Neeladri Sekhar Roy, Sally L. Shirran, Megan Bergkessel, Marc Devocelle, Clarissa M. Czekster

    Pseudomonas aeruginosa is an adaptable organism, frequently found in chronic infections, and for which antimicrobial resistance is a growing concern. Therefore, there is an urgent need for alternative therapeutic strategies. Cationic antimicrobial peptides (AMPs) offer potent bactericidal activity but suffer from limited selectivity and potential host toxicity. To enhance species-specific targeting, we designed two prodrug variants of the AMP D-Bac8CLeu2,5─EEEE-D-Bac8CLeu2,5 and ELEG-D-Bac8CLeu2,5─engineered for activation by the P. aeruginosa extracellular aminopeptidase PaAP. While both prodrug motifs effectively neutralized the positive charge of D-Bac8CLeu2,5 and prevented DNA–peptide complex formation, EEEE-D-Bac8CLeu2,5 showed negligible antimicrobial activity due to slow and incomplete activation. In contrast, ELEG-D-Bac8CLeu2,5 underwent rapid PaAP-mediated activation, restoring bactericidal activity in planktonic cultures and biofilms. PaAP contributed significantly to complete prodrug activation, particularly within biofilms, where the accumulation of partially activated intermediates correlated with biphasic killing kinetics. The prodrug showed reduced activity against other ESKAPEE pathogens, demonstrating selective activation by P. aeruginosa. Experiments selecting resistant bacteria revealed distinct mutations in lipopolysaccharide biosynthesis pathways for D-Bac8CLeu2,5 and the prodrug, with limited cross-resistance. These findings establish aminopeptidase-activated AMP prodrugs as a promising approach for species-selective antimicrobial therapy and highlight the feasibility of exploiting bacterial enzymes for controlled antimicrobial peptide activation.

  • Open Access

    Bacterial Aminopeptidase–Activated Peptide Prodrug Enables Species-Selective Targeting of Pseudomonas aeruginosa

    by Qingtian Gong, Silvia Synowsky, Aisling Lynch, John R. F. B. Connolly, Neeladri Sekhar Roy, Sally L. Shirran, Megan Bergkessel, Marc Devocelle, Clarissa M. Czekster

    Pseudomonas aeruginosa is an adaptable organism, frequently found in chronic infections, and for which antimicrobial resistance is a growing concern. Therefore, there is an urgent need for alternative therapeutic strategies. Cationic antimicrobial peptides (AMPs) offer potent bactericidal activity but suffer from limited selectivity and potential host toxicity. To enhance species-specific targeting, we designed two prodrug variants of the AMP D-Bac8C Leu2,5 – EEEE□-Bac8C Leu2,5 and ELE□ D-Bac8C Leu2,5 —engineered for activation by the P. aeruginosa extracellular aminopeptidase PaAP. While both prodrug motifs effectively neutralized the positive charge of D-Bac8C Leu2,5 and prevented DNA–peptide complex formation, EEEE□-Bac8C Leu2,5 showed negligible antimicrobial activity due to slow and incomplete activation. In contrast, ELEG□-Bac8C Leu2,5 underwent rapid PaAP□mediated activation, restoring bactericidal activity in planktonic cultures and biofilms. PaAP contributed significantly to complete prodrug activation, particularly within biofilms, where the accumulation of partially activated intermediates correlated with biphasic killing kinetics. The prodrug showed reduced activity against other ESKAPEE pathogens, demonstrating selective activation by P. aeruginosa . Experiments selecting resistant bacteria revealed distinct mutations in lipopolysaccharide biosynthesis pathways for D-Bac8C Leu2,5 and the prodrug, with limited cross□resistance. These findings establish aminopeptidase□activated AMP prodrugs as a promising approach for species□selective antimicrobial therapy and highlight the feasibility of exploiting bacterial enzymes for controlled antimicrobial peptide activation.